By Ellen ‘t Hoen, Global Health Unit Department of Health Sciences, UMCG Groningen, email@example.com.
This month the European Commission published Innovative Payment Models for High-Cost Innovative Medicines, a report of the Expert Panel on effective ways of investing in Health (EXPH).
The report examines new ways of paying for new and costly medicines as a means to finding solutions for the ever-increasing prices of new pharmaceutical treatments. The panel does not shy away from exploring hot-button topics such as the need for greater transparency in medicines pricing, R&D and marketing cost, enlisting competition authorities to investigate drug pricing, ‘orphanisation’ of new medicines, revisiting the patent and market exclusivity as a cornerstone of innovation, developing alternative paths for innovation financing based on delinkage principles such as prize awards and the question how to ensure a ‘public return on public investment’. It further explores ways to bolster negotiating power of governments in price negotiations, including through the use of compulsory licensing of medicines patents.